BioSpace News Archive

Windtree Therapeutics, Inc., a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, reported financial results for the third quarter ended September 30, 2021 and provided key business updates.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, provided an update on recent company developments and reported third quarter financial results for the period ended September 30, 2021.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter ended September 30, 2021.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced financial results for the quarter ended September 30, 2021.

MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announced third quarter ended September 30, 2021 financial results.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Histogen Inc. (NASDAQ: HSTO), today reported financial results for the third quarter ended September 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

Femasys Inc., a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced financial results for the third quarter and nine months ended September 30, 2021 and provided a corporate update on the Company’s business and clinical programs.

NeuroPace, Inc., today announced that it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to study the company’s RNS® System in patients with drug-resistant idiopathic generalized epilepsy.

Marrone Bio Innovations, Inc., an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021.